ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBPBiotechnology
+$0.44 today
- Market cap
- $563.78M
- Beta
- 1.42
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$3.22
Volume 2.70M
Average 0.50M
AVBP Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses dips below year-ago levels
Q1 FY2026 operating expenses of $46.11M fell 30.9% year over year, behind the +11.7% change in trailing-twelve-month operating expenses. Sequentially, it rose 18.8% from the prior quarter. Over 3 fiscal years it compounded at +68.8% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -30.9% toward the trailing-twelve-month pace of +11.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 177.53M USD
- Year-over-year change
- +88.2%
- 4-year CAGR
- +112.6%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 177.53M | +88.2% |
| FY2024 | 2024-12-31 | 94.31M | +26.4% |
| FY2023 | 2023-12-31 | 74.59M | +102.1% |
| FY2022 | 2022-12-31 | 36.91M | +324.4% |
| FY2021 | 2021-12-31 | 8.7M | — |
Operating Expenses vs competitors
How AVBP compares with its peers on the latest reported figures
- AVBP's LTM Mar 2026 operating expenses of $156.87M is the 6th highest of the 11 companies compared; the peer median is $156.68M.
- Its year-over-year change of +11.7% is the 4th highest of 11, against a peer median of +1.5%.
- Over three fiscal years its annual growth of +68.8% compares with a peer median of -1.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $1.38B | -5.2% | +0.3% | 56.6% | |
| LTM Jun 2026 | $517.9M | +0.8% | -3.3% | 115.2% | |
| LTM Jun 2026 | $297.23M | +30.0% | +30.7% | 174.9% | |
| LTM Sep 2026 | $176.19M | +23.1% | -19.4% | — | |
| LTM Mar 2026 | $163.78M | -44.2% | +49.7% | 72.7% | |
| LTM Mar 2026 | $156.87M | +11.7% | +68.8% | — | |
| LTM Mar 2026 | $149.59M | +2.2% | +15.6% | — | |
| LTM Mar 2026 | $142.77M | +25.7% | +31.1% | — | |
| LTM Mar 2026 | $139.67M | +6.4% | -3.8% | 61.5% | |
| LTM Jun 2025 | $73.46M | +0.2% | -20.0% | 12.2% | |
| LTM Mar 2026 | $53.18M | -28.1% | -18.7% | — | |
| Peer median (excluding AVBP) | $156.68M | +1.5% | -1.5% | 67.1% | |
Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 6.43M | 30.43M | 64.88M | 79M | 153.35M |
| Selling, General & Admin | 2.26M | 6.47M | 9.71M | 15.3M | 24.18M |
| Operating Expenses | 8.7M | 36.91M | 74.59M | 94.31M | 177.53M |
| Depreciation & Amortization | 0 | 36.91M | 0 | 0 | 0 |
| EBITDA | (51.61M) | 0 | (69.33M) | (80.49M) | (166.31M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (8.7M) | (36.91M) | (74.59M) | (94.31M) | (177.53M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 5.26M | 13.82M | 11.23M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (42.91M) | 0 | 5.26M | 13.82M | 11.23M |
| Income Before Tax | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (40.44) | (1.10) | (2.17) | (2.56) | (4.32) |
| EPS (Diluted) | (40.44) | (1.10) | (2.17) | (2.56) | (4.32) |
| Weighted Avg Shares | 1.28M | 33.49M | 31.96M | 31.47M | 38.46M |
| Weighted Avg Shares (Diluted) | 1.28M | 33.49M | 31.96M | 31.47M | 38.46M |
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.